Related references
Note: Only part of the references are listed.Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review
Maria-Victoria Mateos et al.
BMC CANCER (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma
Siyang Leng et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data
Christopher Kim et al.
SUPPORTIVE CARE IN CANCER (2018)
Bisphosphonates in multiple myeloma: an updated network meta-analysis
Rahul Mhaskar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015
A. Khan et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Multiple myeloma: practice patterns across Europe
Marc S. Raab et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study
Makoto Kajizono et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Ramon Garcia-Sanz et al.
HAEMATOLOGICA (2015)
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
W. I. Gonsalves et al.
BLOOD CANCER JOURNAL (2015)
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Ramon Garcia-Sanz et al.
HAEMATOLOGICA (2015)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma
K. M. Sanfilippo et al.
LEUKEMIA & LYMPHOMA (2015)
Bone health in cancer patients: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Optimal use of bisphosphonates in patients with multiple myeloma
Evangelos Terpos et al.
BLOOD (2013)
Bisphosphonates in multiple myeloma: a network meta-analysis
Rahul Mhaskar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients
Sandra K. Thygesen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Biochemical and molecular mechanisms of action of bisphosphonates
Michael J. Rogers et al.
BONE (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
The Danish Civil Registration System
Carsten Bocker Pedersen
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
AS Levey et al.
ANNALS OF INTERNAL MEDICINE (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
RN Pearse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
